IE
CURX

Israel Englander’s Curanex Pharmaceuticals CURX Stock Holding History

Israel Englander’s Portfolio CURX Stock Details CURX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-958
Closed -$13.8K – 6633
2025
Q3 		$13.8K Buy
+958
New +$86.7K ﹤0.01% 5883

Other funds holding CURX

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $4.11B AUM 21.98% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $12.4B AUM 62.79% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Israel Englander's CURX Position: Q4 2025 in Review

Israel Englander sold out of Curanex Pharmaceuticals (CURX) in Q4 2025, closing a stake of 958 shares — an estimated $13.8K sold.

Israel Englander first reported a position in CURX in Q3 2025 and held it in 1 quarter. The position peaked at $13.8K in Q3 2025. 11 funds tracked by Wall St. Rank hold CURX as of Q4 2025.

  • Israel Englander reported no remaining Curanex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Israel Englander sold 958 Curanex Pharmaceuticals shares in Q4 2025, an estimated $13.8K.
  • Israel Englander first reported a position in Curanex Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Israel Englander's Curanex Pharmaceuticals position peaked at $13.8K in Q3 2025.
  • 11 funds tracked by Wall St. Rank held Curanex Pharmaceuticals as of Q4 2025.

Based on Millennium Management's 13F filing for Q4 2025, filed 17 Feb 2026.